Search
Flurbiprofen
go.drugbank.com/drugs/DB00712ApprovedInvestigationalFlurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. … Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity.
Categories: Antiinflammatory Preparations, Non-Steroids for Topical UseChlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnDue to the long terminal half-life of 37 days, the use of chlorobutanol as a sedative is limited because of the considerable accumulation which will occur following multiple dosing [A32743]. … As a long-term stabilizer of multi-ingredient preparations, chlorobutanol is normally used at a concentration of 0.5%. At this concentration, it also conserves its antimicrobial activity.
Rindopepimut
go.drugbank.com/drugs/DB05374InvestigationalThe US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015. … Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.
Categories: Complex MixturesTribromometacresol
go.drugbank.com/drugs/DB13513ExperimentalCategories: Antifungals for Topical Use, Antifungals for Dermatological UseSulbentine
go.drugbank.com/drugs/DB13671ExperimentalCategories: Antifungals for Topical Use, Antifungals for Dermatological UseInulin
go.drugbank.com/drugs/DB00638ApprovedInvestigationalNutraceuticalSince it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
Mixtures: GLP CoreDicoumarol
go.drugbank.com/drugs/DB00266ApprovedIn addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.
Tafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing
Chenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalChenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body.